Cell and Gene Therapy Catapult’s Annual Review 2021 Published on 22nd November 2021 by Cell and Gene Therapy Catapult Share The past year emphasised the strength and world-leading capabilities of the UK cell and gene therapy industry which experienced significant expansion despite the COVID-19 pandemic. The Cell and Gene Therapy Catapult has published its 2021 Annual Review, highlighting that the UK has become a place of choice to set up advanced therapy medicinal products (ATMP) activities, with 29% of European ATMP companies operating in the country. Click here to read the Cell and Gene Therapy Catapult’s Annual Review 2021. Check our related news New data shows cell and gene therapy industry creating new high value jobs and contributing strongly to opportunities across the UK Published on 23 Nov 2021 Biotech start-ups successfully graduate from DATA accelerator programme at Stevenage Bioscience Catalyst Published on 18 Nov 2021 LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science Published on 16 Nov 2021 Back to News Sign up to our weekly SBC newsletter Get notified of upcoming events, recent news and available jobs from the SBC community, straight to your inbox. Follow us on social media Keep up to date with all the latest news. Latest from @SteBioCat Save the date...@OneNucleus will bring together students, early career seekers, employers and universities across 2 days to discuss how to create and access great careers within the Life Science industry. more details here bit.ly/3wSLgIx #lifesciences #biotech #learning pic.twitter.com/s9NgqGb7ww 25th Nov Copyright © 2021 Stevenage Bioscience Catalyst Terms & Conditions Privacy policy Designed and built by Onespacemedia We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked. Accept Decline